JP2015530404A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530404A5
JP2015530404A5 JP2015532965A JP2015532965A JP2015530404A5 JP 2015530404 A5 JP2015530404 A5 JP 2015530404A5 JP 2015532965 A JP2015532965 A JP 2015532965A JP 2015532965 A JP2015532965 A JP 2015532965A JP 2015530404 A5 JP2015530404 A5 JP 2015530404A5
Authority
JP
Japan
Prior art keywords
peptide
active ingredient
conjugate
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015532965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530404A (ja
JP6510410B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2013/008445 external-priority patent/WO2014046481A1/ko
Publication of JP2015530404A publication Critical patent/JP2015530404A/ja
Publication of JP2015530404A5 publication Critical patent/JP2015530404A5/ja
Application granted granted Critical
Publication of JP6510410B2 publication Critical patent/JP6510410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015532965A 2012-09-19 2013-09-17 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 Active JP6510410B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR20120104144 2012-09-19
KR10-2012-0104144 2012-09-19
KR20120109216 2012-09-28
KR10-2012-0109216 2012-09-28
KR20130017046 2013-02-18
KR10-2013-0017169 2013-02-18
KR10-2013-0017046 2013-02-18
KR20130017169 2013-02-18
PCT/KR2013/008445 WO2014046481A1 (ko) 2012-09-19 2013-09-17 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물

Publications (3)

Publication Number Publication Date
JP2015530404A JP2015530404A (ja) 2015-10-15
JP2015530404A5 true JP2015530404A5 (https=) 2016-11-10
JP6510410B2 JP6510410B2 (ja) 2019-05-08

Family

ID=50341702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015532965A Active JP6510410B2 (ja) 2012-09-19 2013-09-17 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物

Country Status (8)

Country Link
US (1) US9631184B2 (https=)
EP (1) EP2899199B1 (https=)
JP (1) JP6510410B2 (https=)
KR (1) KR102201430B1 (https=)
CN (3) CN110028554B (https=)
ES (1) ES2743919T3 (https=)
TW (1) TWI598441B (https=)
WO (1) WO2014046481A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616531B (zh) 2012-09-19 2018-03-01 傑姆維克斯&凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(二)
TWI678374B (zh) 2012-09-19 2019-12-01 韓商傑姆維克斯&凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
US9757473B2 (en) * 2013-07-12 2017-09-12 Gemvax & Kael Co., Ltd. Cell-penetrating peptide and conjugate comprising same
CA2926183C (en) 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー,リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
CN108431021B (zh) * 2015-11-03 2021-09-07 珍白斯凯尔有限公司 具有神经元损失预防和再生效果的肽以及包含该肽的组合物
KR101661912B1 (ko) 2016-01-29 2016-10-04 (주)넥스젠바이오텍 녹색형광단백질-인간 상피세포재생인자 융합단백질을 유효성분으로 포함하는 주름 개선 및 항노화 화장료 조성물
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021225344A1 (ko) * 2020-05-08 2021-11-11 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129222A0 (en) * 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
AU2002363231A1 (en) * 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US7294708B2 (en) * 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
EP2837636B1 (en) 2007-01-29 2018-04-11 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
PL2310044T3 (pl) * 2008-06-16 2017-04-28 Mediolanum Farmaceutici S.P.A. Immunoterapia przeciwnowotworowa
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
KR101169030B1 (ko) * 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
PL2536830T3 (pl) * 2010-02-16 2020-02-28 Ultimovacs As Polipeptydy
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150494A1 (en) * 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
TWI616531B (zh) 2012-09-19 2018-03-01 傑姆維克斯&凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(二)
TWI678374B (zh) 2012-09-19 2019-12-01 韓商傑姆維克斯&凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
KR101778244B1 (ko) * 2014-05-13 2017-09-26 한양대학교 산학협력단 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법

Similar Documents

Publication Publication Date Title
JP2015530404A5 (https=)
JP2016500648A5 (https=)
JP2016500513A5 (https=)
JP2015530358A5 (https=)
Kang et al. A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma
van der Meel et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status
JP2024073589A (ja) エキソソームを標的化する方法
JP6789823B2 (ja) 両末端peg化インテグリン結合性ペプチドおよびその使用方法
JP2011037872A5 (https=)
JP2017538401A5 (https=)
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2015522264A5 (https=)
CN102264755A (zh) 靶向vegfr-1/nrp-1的肽
JP2014526881A5 (https=)
RU2015102027A (ru) Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов
RU2017114673A (ru) Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение
JP2012529293A5 (https=)
CN103788211B (zh) 双功能肽、所述双功能肽与核酸分子形成的复合物以及治疗肿瘤的药物组合物
Wong et al. The therapeutic anticancer potential of marine-derived bioactive peptides: a highlight on pardaxin
CN106456728A (zh) 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
ES2818929T3 (es) Péptidos de unión beta amiloide y sus usos para el tratamiento y el diagnóstico de la demencia de Alzheimer
JP6612063B2 (ja) 悪性神経膠腫分子標的ペプチド
US10597426B2 (en) Polypeptide compound and preparation method and use thereof
US20180244724A1 (en) Polypeptide compound and preparation method and use thereof
EP4282490A3 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy